CIAS
AVDL

Capital Investment Advisory Services’s Avadel Pharmaceuticals AVDL Stock Holding History

Capital Investment Advisory Services’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-200
Closed – – 1372
2019
Q2 		$0 Sell
200
-200
-50% -$344 ﹤0.01% 1387
2019
Q1 		$1K Sell
400
-200
-33% -$452 ﹤0.01% 1143
2018
Q4 		$2K Buy
+600
New +$2.04K ﹤0.01% 1038

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Capital Investment Advisory Services's AVDL Position: Q3 2019 in Review

Capital Investment Advisory Services sold out of Avadel Pharmaceuticals (AVDL) in Q3 2019, closing a stake of 200 shares.

Capital Investment Advisory Services first reported a position in AVDL in Q4 2018 and held it in 3 quarters. The position peaked at $2K in Q4 2018. 44 funds tracked by Wall St. Rank hold AVDL as of Q3 2019.

  • Capital Investment Advisory Services reported no remaining Avadel Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 200 Avadel Pharmaceuticals shares in Q3 2019.
  • Capital Investment Advisory Services first reported a position in Avadel Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Capital Investment Advisory Services's Avadel Pharmaceuticals position peaked at $2K in Q4 2018.
  • 44 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2019.

Based on Capital Investment Advisory Services's 13F filing for Q3 2019, filed 17 Oct 2019.